We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

95 hedge funds and large institutions have $227M invested in Aclaris Therapeutics in 2019 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 25

3.67% less ownership

Funds ownership: 95.46% → 91.79% (-3.7%)

4% less funds holding

Funds holding: 99 → 95 (-4)

21% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 19

21% less capital invested

Capital invested by funds: $289M → $227M (-$61.5M)

76% less call options, than puts

Call options by funds: $68K | Put options by funds: $288K

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
95
Holders Change
-4
Holders Change %
-4.04%
% of All Funds
2.06%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
15
Increased
36
Reduced
25
Closed
19
Calls
$68K
Puts
$288K
Net Calls
-$220K
Net Calls Change
-$336K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$7.4M
2
ECM
Endurant Capital Management
California
+$3.62M
3
Man Group
Man Group
United Kingdom
+$3.44M
4
RSCM
Rock Springs Capital Management
Maryland
+$2.46M
5
Renaissance Technologies
Renaissance Technologies
New York
+$2.2M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.6M
2
FCMI
Foresite Capital Management IV
California
-$5.53M
3
EC
EcoR1 Capital
California
-$4.54M
4
UBS Group
UBS Group
Switzerland
-$4.2M
5
BlackRock
BlackRock
New York
-$3.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$35.3M – – –
Franklin Resources
2
Franklin Resources
California
$24M +$122K +18,392 +0.5%
BlackRock
3
BlackRock
New York
$18.8M -$3.23M -487,902 -13%
BC
4
Broadfin Capital
New York
$12.2M +$1.02M +153,423 +8%
SI
5
Sofinnova Investments
California
$11.4M – – –
D.E. Shaw & Co
6
D.E. Shaw & Co
New York
$11.1M -$2.82M -425,495 -19%
Vanguard Group
7
Vanguard Group
Pennsylvania
$11M +$7.4M +1,116,785 +155%
RSCM
8
Rock Springs Capital Management
Maryland
$10.2M +$2.46M +370,600 +28%
VC
9
Vivo Capital
California
$9.87M – – –
MP
10
MFN Partners
Massachusetts
$8.98M – – –
Man Group
11
Man Group
United Kingdom
$7.1M +$3.44M +519,098 +78%
Fidelity Investments
12
Fidelity Investments
Massachusetts
$6.41M -$6.6M -994,967 -48%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$4.49M +$1.72M +259,611 +53%
RHJA
14
Rice Hall James & Associates
California
$4.19M +$1.05M +158,056 +29%
UBS Group
15
UBS Group
Switzerland
$4.09M -$4.2M -633,721 -48%
State Street
16
State Street
Massachusetts
$3.92M -$526K -79,341 -11%
ACM
17
Aisling Capital Management
New York
$3.8M – – –
Axa
18
Axa
France
$3.58M +$1.43M +216,212 +57%
ECM
19
Endurant Capital Management
California
$3.27M +$3.62M +545,729 New
Geode Capital Management
20
Geode Capital Management
Massachusetts
$2.8M +$577K +87,086 +23%
Northern Trust
21
Northern Trust
Illinois
$2.61M -$62.1K -9,361 -2%
Renaissance Technologies
22
Renaissance Technologies
New York
$2.56M +$2.2M +331,700 +347%
CAM
23
Cormorant Asset Management
Massachusetts
$2.52M -$381K -57,500 -12%
TA
24
Teachers Advisors
New York
$1.58M +$1.37M +206,944 +365%
JP Morgan Chase
25
JP Morgan Chase
New York
$1.47M +$342K +51,660 +27%
1
2 3 4 5

ACRS Hedge Fund Activity: Q1 2019 in Review

95 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2019, worth a combined $227M — down 21% from $289M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of ACRS and 15 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 36 added.

The largest buyer was Vanguard Group, adding an estimated $7.4M. The largest seller was Fidelity Investments, cutting an estimated $6.6M.

  • 95 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2019, down from 99 in Q4 2018.
  • Funds reported $227M of Aclaris Therapeutics stock for Q1 2019, down 21% quarter-over-quarter.
  • 15 funds opened new Aclaris Therapeutics positions in Q1 2019 and 19 closed out, a net change of -4 holders.
  • The largest Aclaris Therapeutics buyer in Q1 2019 was Vanguard Group, an estimated $7.4M added.
  • The largest Aclaris Therapeutics seller in Q1 2019 was Fidelity Investments, an estimated $6.6M sold.

Based on aggregated 13F filings for Q1 2019.